Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
424.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 4.00 (0.939%)
Market Cap: £208.53m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Operational and Trading Update

2 Jun 2020 08:00

RNS Number : 6535O
Zotefoams PLC
02 June 2020
 

Zotefoams plc

("Zotefoams" or "Group")

 

Operational and Trading Update

 

2 June 2020 - Zotefoams, a world leader in cellular materials technology, today provides the following operational and trading update for the second quarter, to date.

 

· Maintained operational continuity throughout April and May despite challenging conditions

· Specified in substantial UK Government PPE contract awarded to largest UK customer, using Plastazote® polyolefin foam

· Expect overall trading for the second quarter to be in line with Board expectations at the time of preliminary results announced on 7 April 2020

· Stronger second half performance expected

· Good liquidity with cash performance in the period since 7 April 2020 in line with expectations

 

The health and safety of our colleagues, their families and our business partners has remained our primary concern. The Group is pleased to report that it has established safe working procedures at each of its sites, which has enabled the business to maintain operational continuity throughout April and May. Alongside this, the Group's supply chain has remained resilient, ensuring that Zotefoams has been able to continue to provide a high level of service to its customers.

 

As anticipated and reflecting the disruption arising from the COVID-19 outbreak on a number of markets, demand conditions have been more challenging during April and May. The Group has taken successful action to manage cost and continues to expect overall trading for the second quarter to be consistent with Board's expectations as at the time of the preliminary results announced on 7 April 2020.

 

Notwithstanding the more challenging conditions in the short term, Zotefoams has been proactive in seeking to identify new business opportunities and is pleased to announce that it will supply Plastazote® polyolefin foams for a substantial new contract awarded to its largest UK customer. The project, which starts immediately and is expected to run for a period of 26 weeks, involves the provision of foam for the UK Government's PPE initiative. This will significantly supplement existing AZOTE® volumes, particularly in the second half of 2020, and reinforces the benefits of the diverse range of applications and markets for the Group's products.

 

While the backdrop remains too uncertain to provide detailed financial guidance at this time, the Board continues to expect a stronger performance in the second half of the year, underpinned by more resilient demand for High-Performance Products. The current outlook for both footwear and T-FIT® technical insulation products in the second half remains positive, while conditions in the commercial aviation market are expected to remain weak.

 

As set out in the Group's results for the year ended 31 December 2019, there has been a significant focus on cash and cost management in response to the COVID-19 situation. A number of actions have been implemented swiftly and effectively, which have resulted in a cash performance in the period since 7 April 2020 in line with expectations at that time.

 

Commenting on the update David Stirling, Group CEO of Zotefoams, said: 

 

"We are delighted and proud that Zotefoams materials have been chosen for the provision of critical PPE equipment for front line workers, including within the NHS. This contract not only reflects the unique benefits of our foam products but also the adaptability of our business to provide solutions across a broad range of market segments.

 

"We remain mindful of the continued level of uncertainty and expect market conditions to remain challenging in the short term. However, this incremental AZOTE® foam order, together with the continued robust HPP pipeline and strong cost management delivered to date, further supports the Board's confidence in the Group's balance sheet strength, its growth strategy and in the long-term prospects of the business."

 

- Ends -

 

Enquiries:

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

 

Gary McGrath, Group CFO

 

 

 

IFC Advisory

+44 (0) 203 934 6630

Graham Herring

Tim Metcalfe

Zach Cohen

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. In addition, Zotefoams owns and licenses patented microcellular foam technology, developed specifically for extrusion applications, from a base in Massachusetts, USA to customers worldwide.

 

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky and Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT®). A third foam-manufacturing site, in Poland, is planned to begin operations in 2020.

 

www.zotefoams.com

 

AZOTE®, ZOTEK®, T-FIT® and Plastazote® are registered trademarks of Zotefoams plc

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFIFSRRRIFIII
Date   Source Headline
27th May 20264:06 pmRNSNotification of Transactions of Directors/PDMRs
27th May 20264:00 pmRNSResult of the 2026 Annual General Meeting
27th May 20267:00 amRNSTrading Update
12th May 20267:00 amRNSInvestor Presentation via Investor Meet Company
11th May 20267:00 amRNSNotification of Transactions of Directors/PDMRs
7th May 20267:00 amRNSIssue of Equity
30th Apr 20261:00 pmRNSFinal Dividend Payment Date
27th Apr 20267:00 amRNS2025 Annual Report and Notice of the 2026 AGM
15th Apr 20269:24 amRNSNotification of Transactions of Directors/PDMRs
31st Mar 20266:06 pmRNSHolding(s) in Company
25th Mar 20269:35 amRNSNotification Of Transactions Of Directors/PDMRs
17th Mar 20267:00 amRNSPreliminary Results
17th Mar 20267:00 amRNSPreliminary Results
16th Mar 20261:24 pmRNSNotification Of Transactions Of Directors/PDMRs
16th Mar 20261:24 pmRNSNotification Of Transactions Of Directors/PDMRs
11th Mar 20267:00 amRNSPreliminary results presentation
11th Mar 20267:00 amRNSPreliminary results presentation
13th Feb 20267:00 amRNSNotification Of Transactions Of Directors/PDMRs
27th Jan 20267:00 amRNSChange of Registered Office Address
22nd Jan 20267:00 amRNSTrading Update
15th Jan 20269:57 amRNSNotification Of Transactions Of Directors/PDMRs
15th Dec 20257:00 amRNSNotification Of Transactions Of Directors/PDMRs
18th Nov 202512:39 pmRNSAcquisition of Overseas Konstellation Company S.A.
12th Nov 20254:12 pmRNSNotification Of Transactions Of Directors/PDMRs
4th Nov 20257:00 amRNSTrading Update
24th Oct 20257:00 amRNSNon-Executive Directorate Changes
14th Oct 20252:54 pmRNSNotification Of Transactions Of Directors/PDMRs
9th Oct 20257:00 amRNSNotification Of Transactions Of Directors/PDMRs
30th Sep 20254:25 pmRNSNOTIFICATION OF TRANSACTIONS OF DIRECTORS/PDMRs
22nd Sep 20252:33 pmRNSGroup CFO succession
12th Sep 20255:11 pmRNSNotification Of Transactions Of Directors/PDMR
28th Aug 20257:00 amRNS-RInnovation Initiatives and Executive Appointment
19th Aug 20252:16 pmRNSHolding(s) in Company
14th Aug 20256:19 pmRNSHolding(s) in Company
12th Aug 20252:57 pmRNSNotification Of Transactions Of Directors/PDMR
8th Aug 20257:00 amRNSHolding(s) in Company
7th Aug 202512:14 pmRNSHolding(s) in Company
5th Aug 20257:01 amRNSJoint Venture Agreement and Executive Appointment
5th Aug 20257:00 amRNSInterim Results
29th Jul 202511:01 amRNSInvestor Presentation via Investor Meet Company
14th Jul 20252:51 pmRNSNotification Of Transactions Of Directors/PDMRs
12th Jun 20252:41 pmRNSNotification of Transactions of Directors/PDMRs
10th Jun 20254:13 pmRNSNotification Of Transactions Of Directors/PDMRs
22nd May 202512:30 pmRNSResult of the 2025 Annual General Meeting
22nd May 20257:00 amRNSTrading Update
13th May 202512:05 pmRNSNotification Of Transactions Of Directors/PDMRs
1st May 20257:00 amRNSNotification Of Transactions Of Directors/PDMRs
30th Apr 20257:00 amRNSGroup CFO succession
24th Apr 20257:00 amRNSNotification Of Transactions Of Directors/PDMRs
22nd Apr 20257:00 amRNS2024 Annual Report & Notice of 2025 AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.